Press Release from NCI: Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

The latest press release from the National Cancer Institute

Having trouble viewing this email? View it as a Web page.

You are subscribed to Press Releases from the National Cancer Institute. New press releases are listed below.     Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma 06/19/2024 More than half of clinical trial participants treated with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) had substantial tumor shrinkage. Of those, 38% had tumors that disappeared completely.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892